Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman(Hamilton General Hospital), Samuel Z. Goldhaber(Brigham and Women's Hospital), Sebastian Schellong(Krankenhaus Dresden-Friedrichstadt), Anne Mathilde Kvamme(Boehringer Ingelheim (Norway)), David Baanstra(Boehringer Ingelheim (Netherlands)), Ajay K. Kakkar(Queen Mary University of London), Patrick Mismetti, Clive Kearon(McMaster University), Henry Eriksson(Sahlgrenska University Hospital), Jeffrey Friedman(Boehringer Ingelheim (United States))
Cited by 988
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k